|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01515 CR MEDICAL
Nominal 
3.780 +0.020 (+0.532%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 9,854,790 | -2.500% | 10,107,500 | 7,901,287 | 4,447,477 | 2,750,650 |
| Cost of Sales | (8,044,964) | -1.911% | (8,201,663) | (6,595,452) | (3,513,922) | (2,114,143) |
| Gross Profit | 1,809,826 | -5.038% | 1,905,837 | 1,305,835 | 933,555 | 636,507 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | (32,153) | -84.610% | (208,926) | (510) | -- | -- | |
| Change in FV & Impairment on Others | (7,921) | -97.090% | (272,228) | (136,130) | (355,289) | (23,525) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 98,603 | 8.618% | 90,780 | 88,068 | 83,554 | 34,968 | |
| Profit / (Loss) before Taxation | 838,670 | 70.143% | 492,921 | 422,941 | 270,475 | 418,185 | |
| Taxation | (166,923) | 1.146% | (165,031) | (94,660) | 155,389 | (97,864) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (105,872) | 50.793% | (70,210) | (62,426) | (7,949) | (10,190) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 565,875 | 119.604% | 257,680 | 265,855 | 417,915 | 310,131 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 61,063 | 31.313% | 46,502 | (22,202) | (59,612) | (62,539) |
| Depreciation & Amortisation | 618,896 | 1.315% | 610,863 | 486,406 | 182,879 | 113,382 |
| Directors' Emoluments | -- | -- | 10,515 | 10,618 | 13,079 | 18,418 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 45.000 | 125.000% | 20.000 | 21.000 | 33.000 | 25.000 |
| DPS (cts) | 13.200 | -- | 6.000 | 3.344 | 10.238 | 7.400 |
| Dividend Payout Ratio (%) | 29.333% | -- | 30.000% | 15.923% | 31.024% | 29.600% |
| Cash flow per share ($) | 1.005 | -- | 0.945 | 0.684 | 0.566 | 0.513 |
| NBV per share ($) | 4.792 | -- | 4.482 | 7.331 | 4.975 | 4.709 |
| Remarks: | Real time quote last updated: 14/05/2025 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 565,875 |
| %Change | 119.604% |
| EPS / (LPS) | RMB 0.450 |
| NBV Per Share (¥) | RMB 4.792 |